Novartis AG (NVS)

NYSEHealthcare

$143.97
+$0.19 (+0.1%)

January 21, 2026 at 19:17 UTC

Interactive Chart
NVS
1H
3H
6H
12H
1D
1W
1M
3M
6M
12M (YTD)
2Y
5Y
All
About Novartis AG

Name

Novartis AG

CEO

Vasant Narasimhan

Industry

Healthcare

Year Founded

1996

Employees

75,883

Novartis AG is a pharmaceutical company that discovers, develops, and supplies medicines for conditions managed in specialty and primary care. Its model connects research with manufacturing and patient access so new therapies move from trials to practice under consistent standards. Programs focus on areas where evidence, careful dosing, and long follow-up matter, which is why labeling clarity and clinician education sit alongside science as core work. Supply chains and quality systems are organized for continuity rather than spectacle, keeping availability steady once treatment becomes part of care. Country teams adapt to local frameworks while holding to shared safety principles. Within the healthcare sector, Novartis acts as a long-horizon manufacturer and science organization, turning complex research into options that clinicians can use predictably in hospitals and clinics around the world.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 15 Buy, 4 Hold, 2 Sell
Buy15
Hold4
Sell2
Fundamentals & Financials
Revenue (TTM)
$56.3B
Net Income (TTM)
$14.3B
EPS (TTM)
$5.94
ROA (TTM)
13.42%
Current Ratio
0.88
Dividend Yield
0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)
ItemQ3 2025
Revenue$14,358M
Cost of Sales$3,539M
Gross Profit$10,819M
Operating Income$4,501M
Net Income$3,928M
EPS$0.62
Technical Indicators

Novartis AG's Technical Indicators Summary

NVS is exhibiting a bullish trend supported by a strong ADX reading near 30, indicating solid trend strength. Momentum remains positive as reflected by the MACD and CCI, while the RSI suggests the stock is nearing overbought levels but still holding steady. Price action is comfortably above key moving averages, including the 200-day, reinforcing underlying strength. Although volatility appears moderate with the ATR signaling stability, volume confirms buying interest through a rising On-Balance Volume. Despite some caution from shorter-term oscillators signaling potential pullbacks, the overall technical picture favors sustained upward momentum. The technical takeaway is that NVS maintains a robust bullish stance with healthy trend and momentum indicators.

Buy
15 signals
Neutral
4 signals
Sell
2 signals
Overall: Bullish71% Bullish signals
IndicatorValue
RSI (14)
66.89
Stochastic %K (14, 3, 3)
83.33
CCI (20)
111.84
WPR (14)
-18.61
Momentum (10)
5.80
MFI
52.15
MACD Level (12, 26)
2.82
Bollinger Bands
$134.48 - $145.71
ATR (14)
$2.36 (1.63%)
ADX (14)
29.66
OBV
53,257,400
Simple Moving Averages
$123.15 - $142.22(5 indicators)
Exponential Moving Averages
$123.84 - $142.29(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

NVS opened firmer and now trades 0.383% above yesterday’s close at 144.13. Sector performance is mildly positive at 1.05%, providing a small boost to sentiment. NVS opens firmer, buoyed by sector growth and news on carcinoid tumor market expansion.

Price Change

from $143.58 close

+$0.55

Trading Volume

Below avg (1.8M)

1M

vs S&P 500 Today

Moderate Outperformance

+0.36%

52-Week Position

Near highs

95.4%

Updated: January 21, 2026 at 17:32 UTC

Quote Summary
OpenPrevious Close
$143.82$143.58
Day Range52 Week Range
$143.47 - $144.75$97.72 - $146.35
VolumeAvg. Volume
1.2M1.6M
Market CapP/E Ratio
$277.5B19.7